Metabolic, Circadian trading halted ahead of trial results

By Staff Writers
Thursday, 09 December, 2004

Trading in shares of Metabolic Pharmaceuticals (ASX:MBP) and Circadian Technologies (ASX:CIR) was halted today, in advance of the release of data from Phase IIb trials of Metabolic's obesity drug, AOD9604.

Circadian is Metabolic's largest shareholder, owning 21 per cent of shares.

Babies of stressed mothers likely to get their teeth earlier

Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...

Customised immune cells used to fight brain cancer

Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...

Elevated blood protein levels predict mortality

Proteins that play key roles in the development of diseases such as cancer and inflammation may...

Content from other channels on our network

Could this tailored heart pump transform care for half of heart failure patients?

Monash University tailored heart pump — laboratory set-up

Minderoo Children's Comprehensive Cancer Centre, Randwick

Hospital fined $230K after aged care chair detachment

Helping to keep health care professionals hands-on

Vaxxas secures TGA licence to manufacture vaccine patch technology

DroneShield nabs another European military contract

Daikin Australia opens new Sydney factory

AR3 to be first to process rare earths at ANSTO's new pilot facility

Defence Trailblazer funding manufacturing to help Defence and industry transition to clean energy

Sustainability in 2026: what's next for Australian businesses?

How Australia can increase its circularity rate

$25m grant supports cleaner cement production

Bürkert team to take on sustainability strategies

ASC certifies NT barramundi farm